Try our Advanced Search for more refined results

Deals Rumor Mill: Lonza Group, IDT, Deutsche Bank

By Benjamin Horney (April 13, 2016, 6:55 PM EDT) -- Swiss biotechnology firm Lonza Group AG has made an offer to buy drug development and delivery company Catalent Inc., The New York Times reported on Wednesday. According to the report, Lonza is hoping to acquire Catalent as a way to boost its life sciences capabilities, and a deal could value the New Jersey-based company at nearly $4 billion. Thus far, the two sides are still in disagreement over the price tag, the report noted, and it's possible negotiations could fall apart. If that does happen, Lonza will seek to make a different acquisition, the report said, though it was not clear what company might be next in line....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!